This morning’s additional Phase IIa data on the hRPC programme in Retinitis Pigmentosa (RP) is very encouraging, with all treated patients to date demonstrating an improvement in visual acuity from baseline. We look forward to more detailed results to be released on 12th October at the American Academy of Ophthalmology Annual Meeting (AAO) in San Francisco. As a reminder, RP is a large Orphan disease (around 100,000 cases in the US pa) with no current treatment options. The disease affe
02 Oct 2019
Additional positive Phase II data in Retinitis Pigmentosa
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Additional positive Phase II data in Retinitis Pigmentosa
ReNeuron Group plc (RENE:LON) | 0 0 0.0% | Mkt Cap: 1.74m
- Published:
02 Oct 2019 -
Author:
Jens Lindqvist -
Pages:
3
This morning’s additional Phase IIa data on the hRPC programme in Retinitis Pigmentosa (RP) is very encouraging, with all treated patients to date demonstrating an improvement in visual acuity from baseline. We look forward to more detailed results to be released on 12th October at the American Academy of Ophthalmology Annual Meeting (AAO) in San Francisco. As a reminder, RP is a large Orphan disease (around 100,000 cases in the US pa) with no current treatment options. The disease affe